Analysis of urine biomarkers for early determination of acute kidney injury in non-septic and non-asphyxiated critically ill preterm neonates

J Matern Fetal Neonatal Med. 2017 Feb;30(3):302-308. doi: 10.3109/14767058.2016.1171311. Epub 2016 Apr 21.

Abstract

Objective: We designed the present study to test the hypothesis that urinary biomarkers might predict acute kidney injury (AKI) development in non-septic and non-asphyxiated critically ill preterm infants. We evaluated urine (u) sistatin-C (uCys-C), kidney injury molecule-1 (uKIM-1) and neutrophil gelatinase associate lipocaline (uNGAL) as markers of AKI.

Methods: Sixty-four preterm infants with gestational age between 28 and 32 weeks were included in this study. Biomarkers were measured on day of life (DOL) 1, 3, and 7.

Results: uNGAL levels in the AKI group were significantly higher than in no-AKI group on DOL 1, 3 and 7 (p = 0.016, p = 0.007 and p = 0.0014, respectively).

Conclusions: uNGAL is sensitive, early, and noninvasive AKI biomarkers, increasing significantly in non-septic and non-asphyxiated critically ill preterm neonates.

Keywords: Acute kidney injury; kidney injury molecule–1; neutrophil gelatinase associate lipocaline; preterm infants; sistatin–C; urine.

Publication types

  • Clinical Trial

MeSH terms

  • Acute Kidney Injury / diagnosis*
  • Acute Kidney Injury / urine
  • Biomarkers / urine
  • Case-Control Studies
  • Critical Illness
  • Cystatin C / urine*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Hepatitis A Virus Cellular Receptor 1 / metabolism*
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases / diagnosis*
  • Infant, Premature, Diseases / urine
  • Lipocalin-2 / urine*
  • Male
  • Prospective Studies
  • Sensitivity and Specificity

Substances

  • Biomarkers
  • CST3 protein, human
  • Cystatin C
  • HAVCR1 protein, human
  • Hepatitis A Virus Cellular Receptor 1
  • LCN2 protein, human
  • Lipocalin-2